FDA — authorised 19 December 2014
- Marketing authorisation holder: CUBIST PHARMS
- Status: approved
🇺🇸 Zerbaxa in United States
FDA authorised Zerbaxa on 19 December 2014
Marketing authorisations
FDA — authorised 19 December 2014
- Application: NDA206829
- Marketing authorisation holder: CUBIST PHARMS LLC
- Local brand name: ZERBAXA
- Indication: POWDER — INTRAVENOUS
- Status: approved
Zerbaxa in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United States
Frequently asked questions
Is Zerbaxa approved in United States?
Yes. FDA authorised it on 19 December 2014; FDA authorised it on 19 December 2014.
Who is the marketing authorisation holder for Zerbaxa in United States?
CUBIST PHARMS holds the US marketing authorisation.